Advances in the neuropharmacology of Parkinsonism

D. B. Calne, J. Kebabian, Ellen Silbergeld, E. Evarts

Research output: Contribution to journalArticle

Abstract

Advances through basic research have elucidated the disturbances of neurotransmitter function in Parkinson's disease, with findings directly applicable to drug therapy. Dopamine has replaced acetylcholine and norepinephrine as the most studied neurotransmitter, with both conceptual and practical developments, exemplified by the hypothesis of cyclic adenosine monophosphate as a 'second messenger', and new therapeutic agents. We now have rationally designed in vitro and in vivo tests for the evaluation of dopaminergic compounds instead of entirely empiric screening procedures. We are starting to identify different categories of dopaminergic receptors and to manipulate them selectively, with gains in understanding the physiologic input to the striatum. Crucial questions remain, including how dopamine modulates striatal output and what causes the parkinsonian degeneration of the nigrostriatal pathway. Developing knowledge on synaptic physiology and pharmacology may lead to better therapy.

Original languageEnglish (US)
Pages (from-to)219-229
Number of pages11
JournalAnnals of Internal Medicine
Volume90
Issue number2
StatePublished - 1979
Externally publishedYes

Fingerprint

Neuropharmacology
Parkinsonian Disorders
Neurotransmitter Agents
Dopamine
Corpus Striatum
Second Messenger Systems
Cyclic AMP
Acetylcholine
Parkinson Disease
Norepinephrine
Pharmacology
Drug Therapy
Therapeutics
Research
In Vitro Techniques

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Calne, D. B., Kebabian, J., Silbergeld, E., & Evarts, E. (1979). Advances in the neuropharmacology of Parkinsonism. Annals of Internal Medicine, 90(2), 219-229.

Advances in the neuropharmacology of Parkinsonism. / Calne, D. B.; Kebabian, J.; Silbergeld, Ellen; Evarts, E.

In: Annals of Internal Medicine, Vol. 90, No. 2, 1979, p. 219-229.

Research output: Contribution to journalArticle

Calne, DB, Kebabian, J, Silbergeld, E & Evarts, E 1979, 'Advances in the neuropharmacology of Parkinsonism', Annals of Internal Medicine, vol. 90, no. 2, pp. 219-229.
Calne, D. B. ; Kebabian, J. ; Silbergeld, Ellen ; Evarts, E. / Advances in the neuropharmacology of Parkinsonism. In: Annals of Internal Medicine. 1979 ; Vol. 90, No. 2. pp. 219-229.
@article{f026ec1be3cb400187fbef23208f1709,
title = "Advances in the neuropharmacology of Parkinsonism",
abstract = "Advances through basic research have elucidated the disturbances of neurotransmitter function in Parkinson's disease, with findings directly applicable to drug therapy. Dopamine has replaced acetylcholine and norepinephrine as the most studied neurotransmitter, with both conceptual and practical developments, exemplified by the hypothesis of cyclic adenosine monophosphate as a 'second messenger', and new therapeutic agents. We now have rationally designed in vitro and in vivo tests for the evaluation of dopaminergic compounds instead of entirely empiric screening procedures. We are starting to identify different categories of dopaminergic receptors and to manipulate them selectively, with gains in understanding the physiologic input to the striatum. Crucial questions remain, including how dopamine modulates striatal output and what causes the parkinsonian degeneration of the nigrostriatal pathway. Developing knowledge on synaptic physiology and pharmacology may lead to better therapy.",
author = "Calne, {D. B.} and J. Kebabian and Ellen Silbergeld and E. Evarts",
year = "1979",
language = "English (US)",
volume = "90",
pages = "219--229",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Advances in the neuropharmacology of Parkinsonism

AU - Calne, D. B.

AU - Kebabian, J.

AU - Silbergeld, Ellen

AU - Evarts, E.

PY - 1979

Y1 - 1979

N2 - Advances through basic research have elucidated the disturbances of neurotransmitter function in Parkinson's disease, with findings directly applicable to drug therapy. Dopamine has replaced acetylcholine and norepinephrine as the most studied neurotransmitter, with both conceptual and practical developments, exemplified by the hypothesis of cyclic adenosine monophosphate as a 'second messenger', and new therapeutic agents. We now have rationally designed in vitro and in vivo tests for the evaluation of dopaminergic compounds instead of entirely empiric screening procedures. We are starting to identify different categories of dopaminergic receptors and to manipulate them selectively, with gains in understanding the physiologic input to the striatum. Crucial questions remain, including how dopamine modulates striatal output and what causes the parkinsonian degeneration of the nigrostriatal pathway. Developing knowledge on synaptic physiology and pharmacology may lead to better therapy.

AB - Advances through basic research have elucidated the disturbances of neurotransmitter function in Parkinson's disease, with findings directly applicable to drug therapy. Dopamine has replaced acetylcholine and norepinephrine as the most studied neurotransmitter, with both conceptual and practical developments, exemplified by the hypothesis of cyclic adenosine monophosphate as a 'second messenger', and new therapeutic agents. We now have rationally designed in vitro and in vivo tests for the evaluation of dopaminergic compounds instead of entirely empiric screening procedures. We are starting to identify different categories of dopaminergic receptors and to manipulate them selectively, with gains in understanding the physiologic input to the striatum. Crucial questions remain, including how dopamine modulates striatal output and what causes the parkinsonian degeneration of the nigrostriatal pathway. Developing knowledge on synaptic physiology and pharmacology may lead to better therapy.

UR - http://www.scopus.com/inward/record.url?scp=0018375021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018375021&partnerID=8YFLogxK

M3 - Article

C2 - 36020

AN - SCOPUS:0018375021

VL - 90

SP - 219

EP - 229

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -